Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Golden Meditech Announces FY2016/2017 Annual Results

      Hospital Management Business Showing Upward Trend, Sunbow O&G Hospital and Qinghe Hospital Will Be The New Growth Momentum

      Sales of Discontinuing Operation Will Enrich Cash Reserve, Expedite Diversified Growth Strategies


      News provided by

      Golden Meditech Holdings Limited

      Jun 28, 2017, 07:17 ET

      Share this article

      Share this article


      HONG KONG, June 28, 2017 /PRNewswire/ --


      For the Year Ended 31 March


      2017

      (HK$'000)

      2016

      (HK$'000)

      Change

      (%)

      Continuing Operations

      Revenue

      230,666

      281,558

      (18.1)

      Healthcare services segment revenue

      65,149

      65,620

      (0.7)

         Hospital management services income

      60,456

      59,688

      1.3

         Medical insurance administration services income 

      4,693

      5,932

      (20.9)

      Medical devices segment revenue

      160,663

      210,670

      (23.7)

      Strategic investments revenue

      4,854

      5,268

      (7.9)

      Gross profit

      97,887

      129,068

      (24.2)

      Loss from operations

      (312,168)

      (265,240)

      17.7

      Finance costs

      (572,119)

      (144,467)

      296.0

      Reversal of impairment loss on investment in Fortress Group Limited ("Fortress")

      734,525

      -

      N/M

      Impairment loss on goodwill

      (294,995)

      -

      N/M





      (Loss)/profit attributable to the Company's equity shareholders
        - Continuing operations
        - Discontinuing operation 

      (147,121)

      (436,770)

      289,649

      (686,512)

      (405,561)

      (280,951)

      (78.6)

      7.7

      N/M

      Basic (loss)/earnings per share (in HK cents)
        - Continuing operations
        - Discontinuing operation

      (5.0)

      (14.7)

      9.7

      (29.1)

      (17.2)

      (11.9)

      (82.8)

      (14.5)

      N/M

      Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, announces today its annual results for the year ended 31 March 2017 (the "Year" or "FY2016/2017").

      During the Year, the results from continuing operations were in line with the management's expectations. The Group's total revenue from continuing operations was HK$230,666,000, decreased by 18.1% year-on-year. Of which, revenue from the healthcare services segment and the medical devices segment accounted for 28.2% and 69.7% (FY2015/2016:23.3% and 74.8%) of the Group's total revenue from continuing operations, respectively. The decline in total revenue from continuing operations was mainly attributable to the 23.7% year-on-year decrease in medical devices revenue. Notably, income from hospital management services, one of the Group's key growth focuses, increased by 1.3% year-on-year (FY2015/2016: a decrease of 5.9% year-on-year). Hospital management services income as a % of total revenue from continuing operations showed an upward trend and reached 26.2% (FY2015/2016: 21.2%). The management believes that the accelerating growth of hospital management business will drive the Group's future development.

      Operating loss from continuing operations was HK$312,168,000, increased by 17.7% year-on-year, primarily due to the increased costs incurred for the startup operation of Sunbow O&G Hospital and an accrual of directors' retirement benefits of HK$35,150,000. Loss attributable to equity shareholders of the Company from continuing operations was HK$436,770,000, increased by 7.7% year-on-year. Increase was attributable to the substantial increase in finance costs and the recognition of impairment loss on goodwill of HK$294,995,000 during the Year, such increase was partially offset by the reversal of impairment loss on investment in Fortress of HK$734,525,000.

      The Group recorded loss attributable to the Company's equity shareholders (including continuing operations and discontinuing operation) of HK$147,121,000, decreased by 78.6% year-on-year; basic loss per share was 5.0 HK cents, decreased by 82.8% year-on-year.

      Mr. Kam Yuen, Chairman and Chief Executive Officer of the Group, said, "The PRC government encourages the emerging industries of strategic importance to carry out industry upgrade and structure optimisation, which benefits the further development of healthcare market in China. We will seize these opportunities and optimise our business structure, hoping to accelerate our growth."

      The Company submitted a non-binding privatisation proposal to the board of directors of China Cord Blood Corporation ("CCBC") (the "Proposed Privatisation") in April 2015. During the process of the Proposed Privatisation, the Group was approached by Nanjing Xinjiekou Department Store Co., Ltd. ("NJXB") in respect of the disposal of its 65.4% fully-diluted equity interest in CCBC. However, NJXB decided to withdraw the application for the China Securities Regulatory Commission's approval of its acquisition of CCBC shares in August 2016, due to the uncertainty in the regulatory policy at that time regarding significant asset restructuring of listed companies in the PRC. Subsequently in September 2016, Sanpower Group Limited *("Sanpower"), the substantial shareholder of NJXB, paid the Company an earnest money of RMB300,000,000 (equivalent to approximately HK$348,867,000 at the date of receipt) to secure alternative arrangements for the sale and purchase of CCBC shares. In December 2016, both the Company and Nanjing Yingpeng Huikang Medical Industry Investment Partnership (Limited Partnership)* reached an agreement on the disposal of the Company's entire 65.4% fully-diluted equity interest in CCBC for a total cash consideration of RMB5,764,000,000 (equivalent to approximately HK$6,398,000,000) (the "Disposal"). The Disposal was approved by the Company's shareholders on 22 March 2017. Mr. Kam Yuen added, "The Disposal not only enables the Group to realise its investment in the business, resulting in sound returns to the shareholders, but also demonstrates the Group's outstanding capabilities in exploring, cultivating and growing high-potential investment projects in the healthcare sector."

      To date, the Disposal has yet to be completed. Meanwhile, the Company terminated the Proposed Privatisation upon receiving a termination letter from CCBC on 13 April 2017.

      The Company made a full impairment provision of approximately HK$760 million against its investment in Fortress (a former associate of the Group) in the fiscal year 2014/2015. The Group is committed to maximising returns for its shareholders. Through several negotiations, the Company entered into settlement agreements with each of PAG Asia I LP and its assignee PAGAC Fortress Holding I Limited and Sanpower (the "Fortress Settlement Agreement" and "Sanpower Settlement Agreement"). According to the Fortress Settlement Agreement, the Group was authorised to recover an outstanding amount of approximately US$250 million (equivalent to approximately HK$1.95 billion) from Sanpower (the "Fortress Unsettled Sum"). In return, the Group agreed to pay PAGAC US$180 million (equivalent to approximately HK$1.40 billion) by three instalments within 18 months. Pursuant to the Sanpower Settlement Agreement, Sanpower agreed to pay the Group US$300 million (equivalent to approximately HK$2.34 billion) by five instalments within 36 months as the final settlement to resolve the claim in relation to Fortress Unsettled Sum. These two settlement agreements were approved by the shareholders on 16 January 2017 and were expected to bring cash of approximately US$120 million (equivalent to approximately HK$936 million) to the Group, which exceeded the abovementioned impairment provision of HK$760 million. During the Year, the Group recognised a reversal of impairment loss on its investment in Fortress of approximately $735 million, as a result of the Fortress Settlement Agreement and Sanpower Settlement Agreement.

      Mr. Kam Yuen continued, "The Group is still undergoing business upgrade and optimisation. In addition, through collaborations with The University of Texas at MD Anderson Cancer Center and a renowned oncologist in the U.S.A., the Group builds up a solid foundation for future development in autoimmune disease therapies and precision medicines therapies."

      As the Disposal has yet to be completed during the Year, the Board did not recommend the payment of a final dividend in respect of the year ended 31 March 2017.

      Continuing Operations

      Healthcare Services Segment

      During the Year, healthcare services revenue decreased slightly by 0.7% year-on-year to HK$65,149,000, accounting for 28.2% of total revenue from continuing operations. Revenue generated from hospital management business and medical insurance administration business were HK$60,456,000 and HK$4,693,000, accounting for 92.8% and 7.2% of healthcare services revenue, respectively.

      Hospital Management Business. Over the years, Shanghai East International Medical Center has achieved a stable development and continued to contribute most of the revenue of hospital management services. In addition, Beijing Sunbow Obstetrics & Gynecology Hospital, which opened in October 2016, started contributing revenue to the Group. Beijing Qinghe Hospital, a specialised hospital of the Group, was searching for the right operation and business models since it obtained its license in late 2015. During the Year, the Group adjusted the cooperation models of its hospital management business. Based on the revised cashflow forecast, the Group recognised an impairment loss of goodwill of HK$294,995,000, as the carrying amount allocated to the hospital management business exceeds its recoverable amount. Despite such impairment, the Group is still confident the adjusted cooperation model will bring future growth to its hospital management business.

      Medical Insurance Administration Business. The Group's self-developed intellectualised claim administration system offers off-site insurance settlement services. This is not only relieves the financial burden of policy holders but also provides comprehensive solutions to local governments. The Group will summarise collaboration experiences with government in order to provide its third-party administrator services to more insurance companies and healthcare institutions in future.

      Medical Devices Segment

      Medical devices revenue decreased by 23.7% year-on-year to HK$160,663,000, accounting for 69.7% of the Group's total revenue from continuing operations. The decrease was mainly attributable to the saturated Autologous Blood Recovery System ("ABRS") market in mid and large-sized hospitals in first-tier cities as well as the intensified price competition. Leveraging on product brand and the adjustment on its ABRSs' selling price, the Group managed to stabilise the sale of medical device consumables. The management will strategically adjust the marketing approach to cope with price competition as well as exploit new medical devices and consumables businesses, in order to ease the declining medical devices revenue.

      Strategic Investments

      The Chinese herbal medicines business recorded an operating loss of HK$23,345,000 during the Year. The Group is working closely with the relevant department regarding the land valuation since it received a possible land resumption notice from the local government in Qingpu District of Shanghai. The Group expects to improve its cash position if the land resumption is successful.

      Cord Blood Storage Business – Discontinuing Operation

      Revenue from the discontinuing operation increased by 7.8% year-on-year to HK$876,201,000 during the Year, which was largely attributable to increased subscribers. Profit from discontinuing operation amounted to HK$291,399,000. No depreciation and amortisation were charged on the assets of the discontinuing operation subsequent to the classification as "assets of disposal group classified as held for sale" on 31 March 2016. Excluding depreciation and amortisation and changes in fair value of financial liabilities at fair value through profit or loss, adjusted profit from discontinuing operation for the fiscal year 2015/2016 was HK$302,842,000.  

      Discontinuing Operation

      For the Year Ended 31 March

      2017

      (HK$'000)

      2016

      (HK$'000)

      Revenue

      876,201

      812,944

      Gross profit

      732,034

      635,261

      Other income

      26,974

      81,549

      Selling and administrative expenses

      (418,277)

      (399,989)

      Impairment loss on available-for-sale securities

      (2,943)

      (10,474)

      Profit from operations

      337,788

      306,347

      Finance costs

      (1,704)

      (3,739)

      Changes in fair value of financial liabilities at fair value through profit or loss

      -

      (597,170)

      Profit/(loss) before tax

      336,084

      (294,562)

      Income tax expense

      (44,685)

      (62,706)

      Profit/(loss) from discontinuing operation

      291,399

      (357,268)

      Outlook

      Looking ahead, Mr. Kam commented, "As a leading integrated healthcare enterprise in China, we expect to drive growth across our existing medical devices and healthcare services businesses by tapping onto diversified business opportunities offered in the healthcare industry. Importantly, the Group plans to further develop its healthcare services business by deploying more resources into expanding the scale as well as strengthening the operation capabilities of its existing hospitals. At the same time, by leveraging on its listing status, the Group will actively explore new healthcare-related business opportunities as well as other investment opportunities, at home and abroad, which will yield considerable returns to the shareholders."

      About Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801)

      Golden Meditech (www.goldenmeditech.com) is a leading integrated-healthcare enterprise in China. It is a first-mover in China, having established its dominant positions in several markets including the medical devices market, the cord blood storage market and the hospital management market in the healthcare industry, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, Golden Meditech will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.

      * The English names are for identification purpose only.

      SEGMENT RESULTS

      Information regarding the Group's reportable segments for the periods ended 31 March 2017 and 2016 is set out below:

      (HK$'000 )

      Continuing Operations

      Discontinuing Operation

      Total

      Medical Devices

      Hospital Management

      Medical Insurance
      Administration

      Chinese Herbal
      Medicines

      Cord Blood

      Storage

      2017

      2016

      2017

      2016

      2017

      2016

      2017

      2016

      2017

      2016

      2017

      2016

      Revenue from External Customers

      124,183

      168,707

      60,456

      59,688

      4,693

      5,932

      4,854

      5,268

      876,201

      812,944

      1,070,387

      1,052,539

      Inter-segment Revenue

      36,480

      41,963

      -

      -

      -

      -

      -

      -

      -

      -

      36,480

      41,963

      Reportable Segment Revenue

      160,663

      210,670

      60,456

      59,688

      4,693

      5,932

      4,854

      5,268

      876,201

      812,944

      1,106,867

      1,094,502

      Reportable Segment Profit/(Loss)

      34,956

      52,473

      (441,865)

      (137,910)

      (31,834)

      (37,359)

      (23,345)

      (16,046)

      340,731

      316,821

      (121,357)

      177,979

      Reportable Segment Profit/(Loss) is Arrived at After Charging/(Crediting):

      Depreciation and Amortisation Charges

      7,838

      8,440

      69,577

      60,535

      9,425

      10,305

      19,108

      21,139

      -

      62,940

      105,948

      163,359

      (Reversal)/Increase of Impairment Loss on Trade Receivables

      (86)

      95

      (356)

      894

      791

      495

      -

      -

      34,095

      24,830

      34,444

      26,314

      Impairment Loss on Goodwill

      -

      -

      294,995

      -

      -

      -

      -

      -

      -

      -

      294,995

      -

      SOURCE Golden Meditech Holdings Limited

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.